Fresh Tracks Therapeutics... (FRTX)
| Bid | n/a |
| Market Cap | 5.56M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.06 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 20,420 |
| Avg. Volume (20D) | 1,889 |
| Open | 0.89 |
| Previous Close | 0.69 |
| Day's Range | 0.89 - 0.94 |
| 52-Week Range | 0.03 - 1.03 |
| Beta | undefined |
About FRTX
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and i...
2 years ago · seekingalpha.com
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call TranscriptFresh Tracks Therapeutics, Inc. (NASDAQ:FRTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chi...
2 years ago · investorplace.com
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent DelistingDelistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Pr...
